ArticleCell death & disease2011
Targeting neonatal ischemic brain injury with a pentapeptide-based irreversible caspase inhibitor.
Article in Cell death & disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 48 citations in OpenAlex.
- Targeting caspase-2 interactions with tau in Alzheimer's disease and related dementias.Translational research : the journal of laboratory and clinical medicine · 2023Review
- Genuine selective caspase-2 inhibition with new irreversible small peptidomimetics.Cell death & disease · 2022Article
- Characterization of caspase-2 inhibitors based on specific sites of caspase-2-mediated proteolysis.Archiv der Pharmazie · 2022Article
- Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314.ACS pharmacology & translational science · 2022Article
- A long way to go: caspase inhibitors in clinical use.Cell death & disease · 2021Review
- The Role of Caspase-2 in Regulating Cell Fate.Cells · 2020Review
- A New Vision for Therapeutic Hypothermia in the Era of Targeted Temperature Management: A Speculative Synthesis.Therapeutic hypothermia and temperature management · 2019Review
- Enhanced autophagy contributes to excitotoxic lesions in a rat model of preterm brain injury.Cell death & disease · 2018Article
- A Model of Perinatal Ischemic Stroke in the Rat: 20 Years Already and What Lessons?Frontiers in neurology · 2018Review
- Cell Death in the Developing Brain after Hypoxia-Ischemia.Frontiers in cellular neuroscience · 2017Review
- Role of Perinatal Inflammation in Neonatal Arterial Ischemic Stroke.Frontiers in neurology · 2017Review
- Mitochondria, Bioenergetics and Excitotoxicity: New Therapeutic Targets in Perinatal Brain Injury.Frontiers in cellular neuroscience · 2017Review
- Perinatal brain damage: The term infant.Neurobiology of disease · 2016Review
- MicroRNA: a connecting road between apoptosis and cholesterol metabolism.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Role of mitochondria in apoptotic and necroptotic cell death in the developing brain.Clinica chimica acta; international journal of clinical chemistry · 2015Review
- Pathophysiology and neuroprotection of global and focal perinatal brain injury: lessons from animal models.Pediatric neurology · 2015Review
- Does Caspase-6 Have a Role in Perinatal Brain Injury?Developmental neuroscience · 2015Article
- Marine compound xyloketal B reduces neonatal hypoxic-ischemic brain injury.Marine drugs · 2014Article
- Mitochondrial dysfunction induced by nuclear poly(ADP-ribose) polymerase-1: a treatable cause of cell death in stroke.Translational stroke research · 2014Review
- A novel in vitro model to study pericytes in the neurovascular unit of the developing cortex.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 6 institutions in 3 countries.
Funding
Abstract
Brain protection of the newborn remains a challenging priority and represents a totally unmet medical need. Pharmacological inhibition of caspases appears as a promising strategy for neuroprotection. In a translational perspective, we have developed a pentapeptide-based group II caspase inhibitor, TRP601/ORPHA133563, which reaches the brain, and inhibits caspases activation, mitochondrial release of cytochrome c, and apoptosis in vivo. Single administration of TRP601 protects newborn rodent brain against excitotoxicity, hypoxia-ischemia, and perinatal arterial stroke with a 6-h therapeutic time window, and has no adverse effects on physiological parameters. Safety pharmacology investigations, and toxicology studies in rodent and canine neonates, suggest that TRP601 is a lead compound for further drug development to treat ischemic brain damage in human newborns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.